Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour to Pay up to $120 Million for China Rights to HER2 Bispecific

publication date: Aug 6, 2018

Harbour Biomed in-licensed China rights to a bispecific antibody that targets HER2-positive cancers from Glenmark Pharma, an Indian-French biopharma, in a $120 million agreement. Harbour, a Boston-Shanghai company, has an option to manufacture GBR 1302 for the Greater China market. The two companies will collaborate to develop clinical data that supports approvals of GBR 1302 in their respective territories. Glenmark will receive an upfront payment and is eligible for development, regulatory and commercial milestones, plus tiered royalties. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital